These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12231075)

  • 1. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.
    Reusch JE
    Am J Cardiol; 2002 Sep; 90(5A):19G-26G. PubMed ID: 12231075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of thiazolidinediones on cardiovascular risk factors.
    Gouda BP; Asnani S; Fonseca VA
    Compr Ther; 2002; 28(4):200-6. PubMed ID: 12506489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
    Ayyobi AF; Brunzell JD
    Am J Cardiol; 2003 Aug; 92(4A):27J-33J. PubMed ID: 12957324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.
    DeFronzo RA; Ferrannini E
    Diabetes Care; 1991 Mar; 14(3):173-94. PubMed ID: 2044434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disorders of lipid metabolism in insulin resistance].
    Müller-Wieland D; Krone W
    Herz; 1995 Feb; 20(1):33-46. PubMed ID: 7713475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of endothelial dysfunction in insulin resistance.
    Hsueh WA; Quiñones MJ
    Am J Cardiol; 2003 Aug; 92(4A):10J-17J. PubMed ID: 12957322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk continuum: implications of insulin resistance and diabetes.
    Hsueh WA; Law RE
    Am J Med; 1998 Jul; 105(1A):4S-14S. PubMed ID: 9707262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance and thrombosis: a cardiologist's view.
    Sobel BE
    Am J Cardiol; 1999 Jul; 84(1A):37J-41J. PubMed ID: 10418858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
    Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes mellitus as a prothrombotic condition.
    Grant PJ
    J Intern Med; 2007 Aug; 262(2):157-72. PubMed ID: 17645584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
    Lebovitz HE
    Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dyslipoproteinemia and metabolic syndrome. Effects of insulin resistance and hyperinsulinemia on lipid metabolism].
    Krone W; Müller-Wieland D; Wirth H
    Fortschr Med; 1992 Dec; 110(34):645-8. PubMed ID: 1483617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
    Florkowski CM
    Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease.
    Fonseca VA
    Am J Cardiol; 2003 Aug; 92(4A):50J-60J. PubMed ID: 12957327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical interest of PPARs ligands.
    Vergès B
    Diabetes Metab; 2004 Feb; 30(1):7-12. PubMed ID: 15029092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.